EGFR and non-small cell lung carcinoma: ,6 In contrast, a clinical trial of chemotherapy with ICIs, including atezolizumab, in NSCLC reported that the combination has therapeutic efficacy in a subgroup analysis of patients with EGFR-mutant NSCLC.7